IIAM Is Now Supporting Therapeutic Applications of Liver Cells
IIAM now provides livers for therapeutic uses and pre-clinical investigations. These efforts are intended to treat patients with advanced cirrhosis and those with rare metabolic disorders, targeting Phenylketonuria (PKU), Alpha-1 antitrypsin deficiency (A1AD) and urea cycle disorders. These diseases are identified by the FDA as having minimal treatment options. They often have a detrimental effect on overall quality of life, and typically result in dramatically shortened lifespans for the patients affected by these disorders.Many of the patients who will be treated are 14-17 years of age.
Hepatocytes and other cells isolated from high quality, non-transplantable livers will be used in a number of U.S. clinical and pre-clinical trials at major medical centers. Treatment options include successive cell transplants or tissue engineered solutions such as liver patches. Time-critical referrals of livers will be necessary, so we are also excited to announce our new donor screening technology that will speed placement.
We are very excited with this latest endeavor to save and heal lives through research and therapy! Click here for full press release.